Vital KSK Holdings, Inc. (VKSKF)
OTCMKTS · Delayed Price · Currency is USD
9.00
0.00 (0.00%)
Feb 11, 2026, 9:30 AM EST
Vital KSK Holdings Revenue
Vital KSK Holdings had revenue of 164.32B JPY in the quarter ending December 31, 2025, with 0.44% growth. This brings the company's revenue in the last twelve months to 604.24B, up 0.83% year-over-year. In the fiscal year ending March 31, 2025, Vital KSK Holdings had annual revenue of 600.37B with 2.19% growth.
Revenue (ttm)
604.24B JPY
Revenue Growth
+0.83%
P/S Ratio
0.11
Revenue / Employee
160.87M JPY
Employees
3,756
Market Cap
437.64M USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 600.37B | 12.89B | 2.19% |
| Mar 31, 2024 | 587.48B | 7.71B | 1.33% |
| Mar 31, 2023 | 579.77B | 2.52B | 0.44% |
| Mar 31, 2022 | 577.25B | 40.22B | 7.49% |
| Mar 31, 2021 | 537.03B | -25.48B | -4.53% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zynex | 108.20M |
| China Medicine | 65.76M |
| PD-Rx Pharmaceuticals | 18.35M |
| Exlites Holdings International | 9.42M |
| Pharmagen | 4.41M |
| Gold Enterprise Group | 559.55K |
| Global Medical Products Holdings | 45.96K |
| DH Enchantment | -42.87K |